Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06680661 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

StatusSuspended
PhasePhase 2
Started2026-04-08
View on ClinicalTrials.gov ↗
The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with blood cancer. The usual therapy for graft versus host disease prevention after a cord blood transplant includes tacrolimus and MMF. The main question this clinical trial aims to answer is whether or not abatacept will be safe and effective in reducing aGVHD rates in dCBT. Participants will: * Partake in exams, tests, and procedures as part of usual cancer care. * Partake in conditioning, which is the treatment that is given before a transplant. * Have a cord blood transplant. * Partake in radiation following the transplant.

Amendment history 1 change detected by DataLookout

2026-09-11
Recruitment suspended: insufficient funding
Trial Details
NCT Number NCT06680661
Lead Sponsor Leland Metheny
Conditions Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome Other, Chronic Myelomonocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Enrollment 20 participants
Start Date 2026-04-08
Primary Completion 2027-10-29 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-10